Moderna Forecast -8.2%: Plunge as $39 Target Alarms Bulls
Can Moderna’s pipeline story outweigh a brutal valuation reset, or is the latest sell-off warning investors not to chase the rally? Maik Kemper Editor in Chief Because it…
Moderna Flu Vaccine -3.4% After FDA Panel Backs Shot
Can the Moderna Flu Vaccine turn an FDA panel win into a real growth story before Wall Street loses patience? Maik Kemper Editor in Chief The 9–0 VRBPAC…
Eli Lilly Medicare Obesity: $15B Market Boom Builds
Can Medicare coverage and faster FDA plant approvals turn Eli Lilly’s obesity franchise into an even bigger profit machine? Maik Kemper Editor in Chief From my perspective, both…
Eli Lilly Record at $1 Trillion as GLP-1 Boom Lifts LLY
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma? Maik Kemper Editor in Chief Lilly’s AI-infused commercial engine is now…
Moderna Strategy +13%: In Vivo CAR-T Surge Lifts MRNA
Can Moderna Strategy turn a vaccine story into a multi-platform biotech growth engine before the market prices it in? Maik Kemper Editor in Chief The in vivo CAR-T…
Pfizer Lung Cancer Trial Sends Warning on Oncology Pivot
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology turnaround? Maik Kemper Editor in Chief Patients with…
Pfizer CFO Transition -2.9%: Stock Drops After CFO Exit
Can Pfizer convince Wall Street this CFO change is about continuity, not a deeper warning on execution and growth? Maik Kemper Editor in Chief Dave has been a…
Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade? Maik Kemper Editor in Chief The oral Wegovy tablet…
Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote
Will Moderna Flu Vaccine finally clear the FDA hurdle, or is Wall Street getting ahead of itself again? Maik Kemper Editor in Chief The immunogenicity data in older…
Eli Lilly Acquisition Signals Pain Drug Boom Beyond GLP-1
Can Eli Lilly’s latest deal prove the company is more than a one-theme GLP-1 growth story? Maik Kemper Editor in Chief The company was focused on four main…